Onconova therapeutics, inc. (ONTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-5,092

-5,747

-4,595

-3,561

-7,600

-5,651

-5,348

-4,321

-5,090

-6,207

-6,960

-2,584

-8,341

-5,447

-1,599

-5,381

-7,240

3,192

-5,873

-8,975

-12,367

-13,392

-14,907

-16,780

-18,716

-14,628

-20,521

-12,562

-14,845

Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

3

3

3

0

8

11

14

14

16

19

22

24

23

24

24

24

24

25

27

26

72

98

97

98

141

120

119

109

98

Change in fair value of warrant liabilities

63

17

-475

-32

427

-143

-129

-513

-812

88

209

-3,474

1,549

-1,003

-2,706

-8

-271

-

-

-

-

0

-1

-3

-16

-61

31

2

-14

Treasury note discount amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

2

-2

5

-

-

-

-

Stock compensation expense

93

98

145

155

650

314

295

260

278

377

431

444

458

572

576

611

2,170

809

791

803

1,383

841

1,586

1,313

1,328

1,076

4,095

379

2,465

Changes in assets and liabilities:
Receivables

-53

-

-

-

-

11

-48

-405

418

2

-176

107

95

-873

-1,243

779

-136

-31

1,268

233

-98

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

145

-

-

-

-

64

151

-269

-6

-180

289

-137

-740

420

193

-178

-679

-69

157

-827

-495

-1,200

1,036

-1,070

14

-939

-541

3,201

941

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-75

-

-

-

-

-

-

-

-

Accounts payable

-88

-253

-226

416

295

-225

-1,685

-392

848

750

-245

274

84

1,252

1,270

-495

-125

231

-995

328

-170

-1,358

358

1,725

-408

-695

-5

167

-1,274

Accrued expenses and other current liabilities

-1,294

347

-322

-79

-324

685

-84

460

-223

236

-629

-293

-361

-100

-1,357

1,948

162

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-56

-57

-57

-56

-57

-57

-114

-113

-114

-114

-113

-114

-113

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-283

-1,157

675

-

738

-1,331

1,975

-1,998

2,479

-221

1,634

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1

-

-1

-1

-3

-23

-17

-17

20

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-114

-114

-113

-114

-8,114

-113

-114

-114

-113

-114

-113

-447

-1,856

-1,092

-591

-1,092

Net cash used in operating activities

-6,463

-5,360

-3,961

-4,909

-6,601

-5,409

-7,154

-4,624

-5,509

-4,673

-7,398

-5,693

-6,056

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,579

-5,040

-7,871

-8,473

-9,854

-14,270

-13,193

-14,020

-16,165

-17,130

-14,370

-15,935

-13,949

Payments for purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

0

150

72

94

42

189

284

Financing activities:
Proceeds from the sale of common stock and warrants, net of costs

9,062

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,000

0

15,000

10,000

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,994

0

14,850

9,928

-94

-40,032

-189

-284

Proceeds from the sale of common stock and warrants, net of costs

-

-

-

-

-

-

0

26,343

8,725

1,043

0

5,277

40

-1

15,814

-2

1,609

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

5,717

4,867

0

0

33

-

0

573

16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

50

45

853

106

45

0

6

Net cash provided by financing activities

14,779

23,255

2,969

391

33

0

0

26,916

8,741

1,043

0

5,277

40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign currency translation on cash

-6

9

-13

4

-6

-5

-2

-16

8

4

9

16

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

8,310

17,905

-1,061

-4,514

-6,574

-5,414

-7,156

22,276

3,240

-3,626

-7,389

-400

-6,011

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,609

-

-

-

-

515

50

45

853

602

79,856

0

6

Effect of foreign currency translation on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-4

-4

29

-30

-5

-8

0

-1

19

-23

-2

7

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,378

12,960

-4,017

-2,964

-2,398

-3,161

-8,340

-9,884

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,385

-16,603

25,431

-16,126

-14,220